ASH Annual Meeting and Exposition

The latest news from ASH, including researcher interviews and physician perspective.


Meeting News

KANK1 associated with higher risk for multiple myeloma among African Americans

January 7, 2020
ORLANDO — Expression of the KANK1 gene appeared associated with higher risk for multiple myeloma among African Americans, according to results…
Meeting News

Discovery of novel fetal hemoglobin repressor may provide ‘new avenues’ for sickle cell disease treatment

January 7, 2020
ORLANDO — Researchers identified the protein nuclear factor IX as a novel repressor of fetal hemoglobin, a discovery that could lead to the…
Meeting NewsPerspective

Dual target CAR T/natural killer cell therapy shows promise for B-cell malignancies

December 27, 2019
ORLANDO — Two major impediments to widespread adoption of chimeric antigen receptor T-cell therapies are their cost and antigen loss that makes…
Meeting NewsPerspective

Oral arginine therapy appears safe, effective for sickle cell disease pain management

December 27, 2019
ORLANDO — Oral supplementation with arginine resulted in faster resolution of pain associated with vaso-occlusive episodes among younger…
Meeting NewsPerspective

Polyfunctional strength index identifies responders to combination immunotherapy in acute myeloid leukemia

December 26, 2019
ORLANDO — Polyfunctional strength index on pretherapy bone marrow CD4-positive T cells differed substantially between responders and…
Meeting News

Erythroferrone may function as negative regulator of bone remodeling in beta-thalassemia

December 26, 2019
ORLANDO — Erythroferrone appeared to function as a negative regulator of osteoblast and osteoclast activity, and its loss can result in…
Meeting News

New gene therapy appears safe, feasible for sickle cell disease

December 26, 2019
ORLANDO — Significant induction of fetal hemoglobin after the infusion of CD34-positive cells occurred among a small cohort of patients with…
Meeting NewsPerspective

Mosunetuzumab induces remissions in advanced non-Hodgkin lymphoma after CAR-T fails

December 23, 2019
ORLANDO — About 20% of a cohort of patients with aggressive relapsed or refractory non-Hodgkin lymphoma experienced complete response to…
Meeting NewsPerspective

Fragmentation of care common among young adults with sickle cell disease

December 23, 2019
ORLANDO — Young adults with sickle cell disease experienced fragmentation of health care during the transition period after childhood…
Meeting NewsVideo

VIDEO: Efgartigimod safe, effective in primary immune thrombocytopenia

December 23, 2019
ORLANDO — A 3-week treatment cycle of efgartigimod, a neonatal Fc receptor antagonist, was well tolerated and effective in patients with…